Opioids are among the most effective analgesics available and are the first choice in the
treatment of acute severe pain. However, partial efficacy, a tendency to produce tolerance …

Evidence that the delta opioid receptor (DOR) is an attractive target for the treatment of brain
disorders has strengthened in recent years. This receptor is broadly expressed in the brain …

Since the serendipitous discovery of the first class of modern antidepressants in the 1950's,
all pharmacotherapies approved by the Food and Drug Administration for major depressive …

Depression is one of the leading causes of disability and a significant health-concern
worldwide. Much of our current understanding on the pathogenesis of depression and the …

Rationale Patients with anxious major depressive disorder (AMDD) have more severe
symptoms and poorer treatment response than patients with non-AMDD. Increasing …

Within the opioid family of receptors, δ (DOP rs) and μ opioid receptors (MOP rs) are typical
GPCR s that activate canonical second‐messenger signalling cascades to influence diverse …

We previously reported that the δ opioid receptor (DOP) agonists SNC80 and TAN-67
produce potent antidepressant-like and antinociceptive effects in rodents. However, SNC80 …

Background and Purpose δ Opioid receptor agonists are being developed as potential
treatments for depression and alcohol use disorders. This is particularly interesting as …

The delta opioid receptor (DOR) has raised much interest for the development of new
therapeutic drugs, particularly to treat patients suffering from mood disorders and chronic …

Opioid therapeutics are excellent analgesics, whose utility is compromised by dependence.
Morphine (1) and its clinically relevant derivatives such as OxyContin (2), Vicodin (3), and …